#USA #Raleigh #Endpoint Clinical #Nagaraja Srivatsan #Arsenal Capital

Nagaraja "Sri" Srivatsan Appointed CEO of Endpoint Clinical

In a significant leadership transition, Endpoint Clinical, an industry frontrunner in randomization and trial supply management solutions, has announced Nagaraja "Sri" Srivatsan as its new Chief Executive Officer. Taking over from an interim position he held since January 2025, Srivatsan's appointment is effective immediately as of March 20, 2025. His extensive experience in clinical research and digital innovation positions him to lead Endpoint into a new era of growth and technological advancements.

Prior to this permanent appointment, Srivatsan joined Endpoint Clinical in January 2024 as an Advisor, where he contributed effectively to refining the company's sales strategy and innovation roadmap. His leadership qualities and commitment to excellence were pivotal in shaping Endpoint's strategic direction during his tenure.

Ray Hill, Chair of the Board and Operating Partner at Arsenal Capital Partners, expressed confidence in Srivatsan's capabilities. Pointing to his strategic vision and commitment to Endpoint's mission, Hill noted that extensive evaluations confirmed Srivatsan as the ideal leader to drive the company’s expansion efforts and technological advancements. The Board believes that under Srivatsan's direction, Endpoint will make significant strides in enhancing clinical trial processes for stakeholders worldwide, including patients, clinical sites, and sponsors.

In his new role, Srivatsan plans to prioritize the advancement of Endpoint’s technology suite, a strategic expansion of the company’s market presence, operational scaling, and the enhancement of solutions aimed at improving clinical trial processes.

"I am honored to lead Endpoint at this exciting time and deeply grateful for the trust placed in me by the Board and our outstanding team," Srivatsan remarked. He emphasized the critical juncture Endpoint finds itself in and the shared mission to transform clinical trial management through innovative and reliable RTSM (Randomization and Trial Supply Management) solutions. His vision for the company focuses on pushing the boundaries of clinical research, ensuring an unmatched level of service and technology for all partners.

Before joining Endpoint, Srivatsan served as Senior Vice President and Chief Digital Officer at IQVIA's Research Development Solutions. He brought a wealth of experience from previous roles, including Chief Growth Officer at EXL and Venture Partner, Emerging Business Accelerator at Cognizant. With over three decades of experience in the clinical trials domain spanning CROs, biopharmaceutical firms, and patient-centered solutions, Srivatsan is well-equipped to lead Endpoint Clinical as it aims to solidify its position as a leader in the eClinical space.

Endpoint Clinical is recognized for its reliable clinical trial technology and service offerings. The company integrates seamlessly into clinical trial operations, delivering anticipatory and adaptive solutions designed to mitigate risks proactively. With a deep understanding of the hurdles faced by manufacturers in clinical trials, Endpoint’s technology-first approach and commitment to innovation empowers manufacturers to focus on executing seamless trials.

About Endpoint Clinical

As a trusted partner in clinical trials, Endpoint Clinical provides cutting-edge RTSM solutions and has decades of experience in understanding the unique challenges that clients encounter in conducting clinical research. Their commitment is complemented by ongoing strategic investments that allow the continuous development of quick and effective solutions in the realm of clinical trial management. For more details on their offerings, visit Endpoint Clinical.

About Arsenal Capital Partners

Arsenal Capital Partners, established in 2000, is a leading private equity investment firm that specializes in building strong industrial growth and healthcare enterprises. With a track record of over $10 billion in institutional equity investment and more than 300 acquisitions, Arsenal partners with management teams to cultivate strategically significant companies that hold leading market positions and exhibit high growth potential. Learn more at Arsenal Capital.